Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Mongersen (GED-0301) in active Crohn's disease
2015-001693-18Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mongersen in Crohn's disease, sponsored by Celgene Corporation. Primary endpoint: Change from baseline of Smad7 expression in the intestinal mucosa. Started Mar 2018; status: terminated.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-001693-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001693-18.